KA
EW icon

Kintegral Advisory’s Edwards Lifesciences EW Stock Holding History

Kintegral Advisory’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.74M Hold
63,507
– – 0.47% 49
2026
Q1 		$5.09M Sell
63,507
-2,816
-4% -$232K 0.48% 51
2025
Q4 		$5.65M Sell
66,323
-1,815
-3% -$149K 0.48% 52
2025
Q3 		$5.3M Sell
68,138
-305
-0.4% -$23.8K 0.45% 62
2025
Q2 		$5.35M Sell
68,443
-103
-0.2% -$7.68K 0.49% 58
2025
Q1 		$4.97M Sell
68,546
-230
-0.3% -$16.5K 0.5% 58
2024
Q4 		$5.09M Sell
68,776
-3,204
-4% -$224K 0.48% 55
2024
Q3 		$4.75M Sell
71,980
-943
-1% -$68.5K 0.44% 69
2024
Q2 		$6.74M Buy
72,923
+40,223
+123% +$3.56M 0.65% 35
2024
Q1 		$3.12M Sell
32,700
-102
-0.3% -$8.57K 0.31% 90
2023
Q4 		$2.5M Sell
32,802
-208
-0.6% -$14.5K 0.28% 99
2023
Q3 		$2.29M Sell
33,010
-20
-0.1% -$1.61K 0.28% 97
2023
Q2 		$3.12M Hold
33,030
– – 0.37% 83
2023
Q1 		$2.73M Sell
33,030
-1,775
-5% -$140K 0.35% 91
2022
Q4 		$2.6M Buy
34,805
+8,697
+33% +$670K 0.34% 95
2022
Q3 		$2.16M Hold
26,108
– – 0.3% 88
2022
Q2 		$2.48M Buy
26,108
+553
+2% +$57.2K 0.32% 82
2022
Q1 		$3.01M Buy
25,555
+571
+2% +$64.1K 0.33% 79
2021
Q4 		$3.24M Hold
24,984
– – 0.34% 71
2021
Q3 		$2.83M Hold
24,984
– – 0.33% 73
2021
Q2 		$2.59M Hold
24,984
– – 0.31% 82
2021
Q1 		$2.09M Hold
24,984
– – 0.27% 95
2020
Q4 		$2.28M Hold
24,984
– – 0.31% 82
2020
Q3 		$1.99M Sell
24,984
-804
-3% -$62.7K 0.3% 82
2020
Q2 		$1.78M Hold
25,788
– – 0.29% 85
2020
Q1 		$1.62M Buy
25,788
+2,886
+13% +$208K 0.32% 84
2019
Q4 		$1.78M Hold
22,902
– – 0.32% 88
2019
Q3 		$1.68M Hold
22,902
– – 0.33% 87
2019
Q2 		$1.41M Hold
22,902
– – 0.29% 99
2019
Q1 		$1.46M Buy
22,902
+7,251
+46% +$414K 0.31% 93
2018
Q4 		$799K Buy
+15,651
New +$792K 0.24% 99

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Kintegral Advisory's EW Position: Q2 2026 in Review

Kintegral Advisory held its Edwards Lifesciences (EW) position steady in Q2 2026 at 63,507 shares worth $5.74M. The position accounts for 0.47% of the portfolio, ranked #49.

Kintegral Advisory first reported a position in EW in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.74M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Kintegral Advisory held 63,507 shares of Edwards Lifesciences worth $5.74M as of Q2 2026.
  • Kintegral Advisory left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.47% of Kintegral Advisory's portfolio in Q2 2026, its #49 holding.
  • Kintegral Advisory first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 31 quarters since.
  • Kintegral Advisory's Edwards Lifesciences position peaked at $6.74M in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Kintegral Advisory's 13F filing for Q2 2026, filed 29 Jul 2026.